AXIS Capital Holdings Limited, through its subsidiaries, provides various specialty insurance and reinsurance products in Bermuda, the United States, and internationally. It operates through two segments, Insurance and Reinsurance. The Insurance segment offers professional insurance products that cover directors' and officers' liability, errors and omissions, employment practices, fiduciary, crime, professional indemnity, medical malpractice, and other financial insurance related coverages for commercial enterprises, financial institutions, not-for-profit organizations, and other professional service providers; and property insurance products for commercial buildings, residential premises, construction projects, property in transit, onshore renewable energy installations, and physical damage and business interruption following an act of terrorism. This segment also provides marine and aviation insurance services for offshore energy, offshore renewable energy, cargo, liability, including kidnap and ransom, fine art, specie, and hull war, hull and liability, and specific war coverage for passenger airlines, cargo operations, general aviation operations, airports, aviation authorities, security firms, and  product manufacturers; personal accident, travel insurance, specialty health products for employer and affinity groups, and pet insurance products; and liability, cyber, and credit and political risk insurance services. The Reinsurance segment offers agriculture, marine and aviation, catastrophe, accidental and health, credit and surety, motor, professional, travel, life, engineering, property, and liability reinsurance products. AXIS Capital Holdings Limited was founded in 2001 and is headquartered in Pembroke, Bermuda.

Axis Capital Holdings Limited

In a report released today, from Jefferies maintained a Buy rating on Axsome Therapeutics, with a price target of $245.00. In addition to Jefferies...

Jefferies Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)

An update from Axsome Therapeutics ( ($AXSM) ) is now available. On April 1, 2026, Axsome Therapeutics announced an asset purchase agreement to acq...

Axsome acquires global rights to Takeda’s balipodect

TD Cowen analyst reiterated a Buy rating on Axis Capital today and set a price target of $130.00. In a report released on March 13, KBW also mainta...

Axis Capital (AXS) Receives a Buy from TD Cowen

In a report released today, Yatin Suneja from Guggenheim maintained a Buy rating on Axsome Therapeutics, with a price target of $245.00. According ...

Guggenheim Keeps Their Buy Rating on Axsome Therapeutics (AXSM)

NAXS AB ( ($SE:NAXS) ) has shared an update. NAXS AB has continued to execute its recently launched share repurchase program, buying back 1,936 sha...

NAXS Advances Share Buyback to Optimize Capital Structure and NAV

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Axsome Therapeutics (AXSM), Monte Rosa Therapeutics ...

Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Monte Rosa Therapeutics (GLUE) and Curis (CRIS)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PolyPid (PYPD) and Axsome Therapeutics (AXSM) with b...

Analysts Are Bullish on Top Healthcare Stocks: PolyPid (PYPD), Axsome Therapeutics (AXSM)

NAXS AB ( ($SE:NAXS) ) just unveiled an update. NAXS AB has initiated a share buyback programme authorized at its 2026 annual general meeting, allo...

NAXS launches share buyback to boost capital flexibility and shareholder value

The latest update is out from NAXS AB ( ($SE:NAXS) ). NAXS AB’s Annual General Meeting approved the 2025 accounts and a dividend of SEK 2.00 per sh...

NAXS AGM Approves Dividend, Board Mandates and Share Buyback Authority

Growth stocks are companies whose sales and earnings are expected to grow faster than the market average, and investors buy them for their future p...

3 Best Growth Stocks to Buy This Week, According to Analysts – March 16-20

An announcement from NAXS AB ( ($SE:NAXS) ) is now available. NAXS AB has continued to execute on its share repurchase program, buying back 5,645 s...

Current Quarter	$3.23	Next Quarter	$3.22
Current Year	$13.3	Next Year	$14.43
QoQ Growth	-0.3%	YoY Growth	+8.5%
3Y EPS CAGR	N/A	Target Price	$123.64
Consensus	Buy	Upside	+20.2%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AXS	$102.89	0.00%	439.06K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AXS	$102.89	0%	439.06K
3
4
5
6

AXS

AXS

EPS Estimates Overview

Quarterly EPS Estimates

Revenue Analysis

Get Axis Capital Holdings Limited Data in Excel

Get Axis Capital Holdings Limited Data in Excel